Introduction: Following the approval of tocilizumab (TCZ) for giant cell arteritis (GCA), recent studies have shown a high relapse frequency after abrupt discontinuation of TCZ. However, a thorough exploration of TCZ tapering compared to abrupt discontinuation has never been undertaken. Likewise, adverse events have only been scarcely investigated in routine care.
View Article and Find Full Text PDFObjectives: To explore current management practices for PMR by general practitioners (GPs) and rheumatologists including implications for clinical trial recruitment.
Methods: An English language questionnaire was constructed by a working group of rheumatologists and GPs from six countries. The questionnaire focused on: 1: Respondent characteristics; 2: Referral practices; 3: Treatment with glucocorticoids; 4: Diagnostics; 5: Comorbidities; and 6: Barriers to research.
Background: In myasthenia gravis (MG), first-line treatment for MG is acetylcholinesterase inhibitors which alleviates symptoms, but concomitantly may cause autonomic adverse effects.
Aims Of The Study: In this study, we evaluated if symptoms of overactive bladder (OAB) are more frequent among MG patients than healthy controls.
Methods: Eighty-three MG patients and 50 healthy sex- and age-matched controls were included and answered the questionnaire "International Consultation on Incontinence Questionnaire Overactive Bladder Module" (ICIQ-OAB), including questions about polyuria, nocturia, urgency, and stress incontinence.
In Denmark, the annual incidence of paranasal malignancies is approximately 60, often presenting with symptoms from growth into neighbouring structures. This case report is of a primary neuroendocrine paranasal tumour with distant metastases in an 81-year-old woman. Following a tooth extraction, the patient developed left side proptosis.
View Article and Find Full Text PDF